drug
(nivolumab + relatlimab)
Marketedupdated 3mo agoby Bristol-Myers Squibb Co
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6all catalysts(0)
nothing on the calendar yet
Trials studying (nivolumab + relatlimab)
News(2)
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…biopharma_dive · 2mo ago
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 3mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that